Dosing & Uses
Dosage Forms & Strengths
tablet: Schedule V
- 50mg (Vimpat)
- 100mg (Vimpat)
- 150mg (Vimpat)
- 200mg (Vimpat)
capsule, extended-release: Schedule V
- 100mg (Motpoly XR)
- 150mg (Motpoly XR)
- 200mg (Motpoly XR)
injectable solution: Schedule V
- 200mg/20mL (Vimpat)
oral solution: Schedule V
- 10mg/mL (Vimpat)
Partial Onset Seizures
Indicated as monotherapy or adjunctive therapy for partial onset seizures
Monotherapy
-
Vimpat
- 100 mg PO/IV q12hr initially, THEN, based on response and tolerability, increase dose at weekly intervals by 50 mg PO/IV BID; up to a recommended dose of 150-200 mg BID (300-400 mg/day) OR
- Alternate initial loading dose schedule: 200 mg PO/IV as a single loading dose, followed 12 hr later by 100 mg PO/IV BID; THEN increase dose at weekly intervals by 50 mg BID; up to a recommended dose of 150-200 mg BID (300-400 mg/day)
-
Motpoly XR
- 200 mg PO qDay, THEN, based on response and tolerability, increase dose at weekly intervals by 100 mg PO qDay; up to a recommended dose of 300-400 mg/day
Adjunctive therapy
-
Vimpat
- Initial: 50 mg PO/IV q12hr
- Based on response and tolerability, increase dose at weekly intervals by 50 mg PO/IV BID; up to a recommended dose of 100-200 mg BID (200-400 mg/day)
-
Motpoly XR
- 100 mg PO qDay, THEN, based on response and tolerability, increase dose at weekly intervals by 100 mg PO qDay; up to a recommended dose of 200-400 mg/day
Conversion from single antiepileptic (AED) to lacosamide monotherapy
-
Vimpat
- Maintain lacosamide at recommended maintenance dose for at least 3 days before initiating withdrawal of the previous AED
- Patients currently treated with a single AED who will convert to lacosamide monotherapy, do not withdraw the concomitant AED until the therapeutic dosage of lacosamide is achieved and has been administered for at least 3 days
- Gradual withdrawal of initial AED over at least 6 weeks is recommended
- When discontinuing Vimpat, gradually withdraw treatment over at least 1 week is recommended
-
Motpoly XR
- Patients currently treated with a single AED who will convert to lacosamide monotherapy, do not withdraw the concomitant AED until the therapeutic dosage of lacosamide is achieved and has been administered for at least 4 days
- Gradual withdrawal of initial AED over at least 6 weeks is recommended
- When discontinuing extended-release lacosamide, a gradual withdrawal over at least 1 week is recommended
Primary Generalized Tonic-Clonic Seizures
Vimpat only
Indicated as adjunctive therapy for primary generalized tonic-clonic seizures
Initial: 50 mg PO/IV q12hr
Based on response and tolerability, increase dose at weekly intervals by 50 mg PO/IV BID; up to a recommended dose of 100-200 mg BID (200-400 mg/day)
Dosage Modifications
Renal impairment
-
Vimpat
- In all patients with renal impairment, base dose initiation and titration on clinical response and tolerability
- Mild to moderate (≥30 mL/min): No dose adjustnt necessary
- Severe (CrCl <30 mL/min) or ESRD: Reduce maximum dosage by 25%
- Hemodialysis: Consider supplementing with up to 50% of dose after 4-hr dialysis session
- Coadministration with strong CYP3A4 or CYP2C9 inhibitors: Lacosamide systemic exposure may increase; consider dose reduction
-
Motpoly XR
- In all patients with renal impairment, base dose initiation and titration on clinical response and tolerability
- Mild to moderate (≥30 mL/min): No dose adjustment necessary
- Severe (CrCl <30 mL/min) or ESRD: Maximum recommended dosage is 300 mg/day
- Hemodialysis: Consider supplementing with up to 50% of dose after 4-hr dialysis session
- Coadministration with strong CYP3A4 or CYP2C9 inhibitors: Lacosamide systemic exposure may increase; consider dose reduction
Hepatic impairment
-
Vimpat
- Mild-to-moderate: Reduce maximum dosage by 25%; observe closely for adverse reactions, and base dose initiation and titration on clinical response and tolerability
- Severe: Not recommended
- Coadministration with strong CYP3A4 or CYP2C9 inhibitors: Lacosamide systemic exposure may increase; consider dose reduction
-
Motpoly XR
- Mild-to-moderate: Maximum recommended dosage is 300 mg/day; observe closely for adverse reactions, and base dose initiation and titration on clinical response and tolerability
- Severe: Not recommended
- Coadministration with strong CYP3A4 or CYP2C9 inhibitors: Lacosamide systemic exposure may increase; consider dose reduction
Dosing Considerations
IV administration indicated as short-term replacement (up to 5 consecutive days) when PO administration is not feasible
Dosage Forms & Strengths
tablet: Schedule V
- 50mg (Vimpat)
- 100mg (Vimpat)
- 150mg (Vimpat)
- 200mg (Vimpat)
capsule, extended-release: Schedule V
- 100mg (Motpoly XR)
- 150mg (Motpoly XR)
- 200mg (Motpoly XR)
injectable solution: Schedule V
- 200mg/20mL (Vimpat)
oral solution: Schedule V
- 10mg/mL (Vimpat)
Partial Onset Seizures
Indicated as monotherapy or adjunctive therapy for partial onset seizures
Vimpat: Indicated as monotherapy or adjunctive therapy for partial-onset seizures in children aged ≥1 month
Motpoly XR: Indicated as monotherapy or adjunctive therapy for partial onset seizures for pediatric patients weighing ≥50 kg
<1 month: Safety and efficacy not established
1 month to 17 years
<6 kg
- Intravenous: 0.66 mg/kg TID, THEN, based on response and tolerability, increase dose at weekly intervals by 0.66 mg/kg TID; up to a recommended 2.5-5 mg/kg TID (7.5-15 mg/kg/day)
- Oral: 1 mg/kg BID (2 mg/kg/day), THEN, based on response and tolerability, increase dose at weekly intervals by 1 mg/kg BID (2 mg/kg/day), up to 3.75-7.5 mg/kg BID (7.5-15 mg/kg/day)
- Alternate initial dose: No loading dose, initiate 3.75 mg/kg PO BID or 2.5 mg/kg IV TID
6 to <30 kg
- 1 mg/kg PO/IV BID, THEN, based on response and tolerability, increase dose at weekly intervals by 1 mg/kg PO/IV BID, up to recommended 3-6 mg/kg PO/IV BID (6-12 mg/kg/day)
- Alternate initial dose: 4.5 mg/kg PO/IV loading dose, THEN, 12 hr later initiate 3 mg/kg PO/IV BID
30 to <50 kg
- 1 mg/kg PO/IV BID, THEN, based on response and tolerability, increase dose at weekly intervals by 1 mg/kg PO/IV BID, up to recommended 2-4 mg/kg PO BID (4-8 mg/kg/day)
- Alternate initial dose: 4 mg/kg PO/IV loading dose, THEN, 12 hr later initiate 2 mg/kg PO/IV BID
≥50 kg
-
Vimpat
- 50 mg PO/IV BID, THEN, based on response and tolerability, increase dose at weekly intervals by 50 mg PO/IV BID, up to recommended 150-200 mg PO/IV BID (300-400 mg/day) for monotherapy or 100-200 mg PO/IV BID (200-400 mg/day) for adjunctive therapy
- Alternate initial dose: 200 mg PO/IV loading dose, THEN, 12 hr later initiate 2 mg/kg PO/IV BID
-
Motpoly XR
- Monotherapy: 100 mg PO qDay, THEN, based on response and tolerability, increase dose at weekly intervals by 100 mg PO qDay; up to a recommended dose of 300-400 mg/day
- Adjunctive therapy: 100 mg PO qDay, THEN, based on response and tolerability, increase dose at weekly intervals by 100 mg PO qDay; up to a recommended dose of 200-400 mg/day
Conversion from single antiepileptic (AED) to lacosamide monotherapy
-
Vimpat
- Maintain lacosamide at recommended maintenance dose for at least 3 days before initiating withdrawal of the previous AED
- Patients currently treated with a single AED who will convert to lacosamide monotherapy, do not withdraw the concomitant AED until the therapeutic dosage of lacosamide is achieved and has been administered for at least 3 days
- Gradual withdrawal of initial AED over at least 6 weeks is recommended
- When discontinuing Vimpat, gradually withdraw treatment over at least 1 week is recommended
-
Motpoly XR
- Patients currently treated with a single AED who will convert to lacosamide monotherapy, do not withdraw the concomitant AED until the therapeutic dosage of lacosamide is achieved and has been administered for at least 4 days
- Gradual withdrawal of initial AED over at least 6 weeks is recommended
- When discontinuing extended-release lacosamide, a gradual withdrawal over at least 1 week is recommended
Primary Generalized Tonic-Clonic Seizures
Indicated as adjunctive therapy for primary generalized tonic-clonic seizures in patients aged ≥4 years with idiopathic generalized epilepsy
<4 years: Safety and efficacy not established
4-17 years
-
11 to <30 kg
- 1 mg/kg PO/IV BID, THEN, based on response and tolerability, increase dose at weekly intervals by 1 mg/kg PO/IV BID, up to recommended 3-6 mg/kg PO/IV BID (6-12 mg/kg/day)
- Alternate initial dose: 4.5 mg/kg PO/IV loading dose, THEN, 12 hr later initiate 3 mg/kg PO/IV BID
-
30 to <50 kg
- 1 mg/kg PO/IV BID, THEN, based on response and tolerability, increase dose at weekly intervals by 1 mg/kg PO/IV BID, up to recommended 2-4 mg/kg PO/IV BID (4-8 mg/kg/day)
- Alternate initial dose: 4 mg/kg PO/IV loading dose, THEN, 12 hr later initiate 2 mg/kg PO/IV BID
-
≥50 kg
- 50 mg PO/IV BID, THEN, based on response and tolerability, increase dose at weekly intervals by 50 mg PO/IV BID, up to recommended 150-200 mg PO/IV BID (300-400 mg/day) for monotherapy or 100-200 mg PO/IV BID (200-400 mg/day) for adjunctive therapy
- Alternate initial dose: 200 mg PO/IV loading dose, THEN, 12 hr later initiate 2 mg/kg PO/IV BID
Dosage Modifications
Renal impairment
-
Vimpat
- In all patients with renal impairment, base dose initiation and titration on clinical response and tolerability
- Mild to moderate (≥30 mL/min): No dose adjustment necessary
- Severe (CrCl <30 mL/min) or ESRD: Reduce maximum dosage by 25%
- Hemodialysis: Consider supplementing with up to 50% of dose after 4-hr dialysis session
- Coadministration with strong CYP3A4 or CYP2C9 inhibitors: Lacosamide systemic exposure may increase; consider dose reduction
-
Motpoly XR
- In all patients with renal impairment, base dose initiation and titration on clinical response and tolerability
- Mild to moderate (≥30 mL/min): No dose adjustment necessary
- Severe (CrCl <30 mL/min) or ESRD: Maximum recommended dosage is 300 mg/day
- Hemodialysis: Consider supplementing with up to 50% of dose after 4-hr dialysis session
- Coadministration with strong CYP3A4 or CYP2C9 inhibitors: Lacosamide systemic exposure may increase; consider dose reduction
Hepatic impairment
-
Vimpat
- Mild-to-moderate: Reduce maximum dosage by 25%; observe closely for adverse reactions, and base dose initiation and titration on clinical response and tolerability
- Severe: Not recommended
- Coadministration with strong CYP3A4 or CYP2C9 inhibitors: Lacosamide systemic exposure may increase; consider dose reduction
-
Motpoly XR
- Mild-to-moderate: Maximum recommended dosage is 300 mg/day; observe closely for adverse reactions, and base dose initiation and titration on clinical response and tolerability
- Severe: Not recommended
- Coadministration with strong CYP3A4 or CYP2C9 inhibitors: Lacosamide systemic exposure may increase; consider dose reduction
Dosing Considerations
IV administration indicated as short-term replacement (up to 5 consecutive days) when PO administration is not feasible
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (0)
Serious - Use Alternative (8)
- apalutamide
apalutamide will decrease the level or effect of lacosamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of apalutamide, a strong CYP3A4 inducer, with drugs that are CYP3A4 substrates can result in lower exposure to these medications. Avoid or substitute another drug for these medications when possible. Evaluate for loss of therapeutic effect if medication must be coadministered. Adjust dose according to prescribing information if needed.
- fexinidazole
fexinidazole will increase the level or effect of lacosamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Fexinidazole inhibits CYP3A4. Coadministration may increase risk for adverse effects of CYP3A4 substrates.
- idelalisib
idelalisib will increase the level or effect of lacosamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Idelalisib is a strong CYP3A inhibitor; avoid coadministration with sensitive CYP3A substrates
- ivosidenib
ivosidenib will decrease the level or effect of lacosamide by affecting hepatic enzyme CYP2C9/10 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP2C9 substrates with ivosidenib or replace with alternate therapies. If coadministration is unavoidable, monitor patients for loss of therapeutic effect of these drugs.
- metoclopramide intranasal
lacosamide, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.
- olopatadine intranasal
lacosamide and olopatadine intranasal both increase sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment.
- tucatinib
tucatinib will increase the level or effect of lacosamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid concomitant use of tucatinib with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. If unavoidable, reduce CYP3A substrate dose according to product labeling.
- voxelotor
voxelotor will increase the level or effect of lacosamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Voxelotor increases systemic exposure of sensitive CYP3A4 substrates. Avoid coadministration with sensitive CYP3A4 substrates with a narrow therapeutic index. Consider dose reduction of the sensitive CYP3A4 substrate(s) if unable to avoid.
Monitor Closely (66)
- alpelisib
alpelisib will decrease the level or effect of lacosamide by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely.
- apalutamide
apalutamide will decrease the level or effect of lacosamide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Coadministration of apalutamide, a weak CYP2C9 inducer, with drugs that are CYP2C9 substrates can result in lower exposure to these medications. Evaluate for loss of therapeutic effect if medication must be coadministered.
- atazanavir
atazanavir increases effects of lacosamide by pharmacodynamic synergism. Use Caution/Monitor. Increased risk of PR prolongation and cardiac arrhythmias.
atazanavir increases levels of lacosamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider decreasing lacosamide dose when coadministered with strong CYP3A4 inhibitors. - cannabidiol
cannabidiol will increase the level or effect of lacosamide by decreasing metabolism. Modify Therapy/Monitor Closely. Cannabidiol may potentially inhibit CYP2C9 activity. Consider reducing the dose when concomitantly using CYP2C9 substrates.
- capecitabine
capecitabine increases levels of lacosamide by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely. Consider decreasing lacosamide dose when coadministered with strong CYP2C9 inhibitors.
- carbamazepine
carbamazepine will decrease the level or effect of lacosamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
carbamazepine increases toxicity of lacosamide by Other (see comment). Use Caution/Monitor. Comment: Coadministration of lacosamide with sodium channel-blocking antiseizure drugs may increase the risk for AV block, bradycardia, or ventricular tachyarrhythmias. Monitor ECG before beginning lacosamide and after lacosamide is titrated to steady-state. - cenobamate
cenobamate will decrease the level or effect of lacosamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase dose of CYP3A4 substrate, as needed, when coadministered with cenobamate.
cenobamate increases toxicity of lacosamide by Other (see comment). Use Caution/Monitor. Comment: Coadministration of lacosamide with sodium channel-blocking antiseizure drugs may increase the risk for AV block, bradycardia, or ventricular tachyarrhythmias. Monitor ECG before beginning lacosamide and after lacosamide is titrated to steady-state. - clarithromycin
clarithromycin increases levels of lacosamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider decreasing lacosamide dose when coadministered with strong CYP3A4 inhibitors.
- conivaptan
conivaptan increases levels of lacosamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider decreasing lacosamide dose when coadministered with strong CYP3A4 inhibitors.
- daridorexant
lacosamide and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment.
- darunavir
darunavir increases levels of lacosamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider decreasing lacosamide dose when coadministered with strong CYP3A4 inhibitors.
- deutetrabenazine
lacosamide and deutetrabenazine both increase sedation. Use Caution/Monitor.
- difelikefalin
difelikefalin and lacosamide both increase sedation. Use Caution/Monitor.
- elagolix
elagolix decreases levels of lacosamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Elagolix is a weak-to-moderate CYP3A4 inducer. Monitor CYP3A substrates if coadministered. Consider increasing CYP3A substrate dose if needed.
- elvitegravir/cobicistat/emtricitabine/tenofovir DF
elvitegravir/cobicistat/emtricitabine/tenofovir DF increases levels of lacosamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider decreasing lacosamide dose when coadministered with strong CYP3A4 inhibitors.
- eslicarbazepine acetate
eslicarbazepine acetate will increase the level or effect of lacosamide by affecting hepatic enzyme CYP2C19 metabolism. Use Caution/Monitor.
eslicarbazepine acetate increases toxicity of lacosamide by Other (see comment). Use Caution/Monitor. Comment: Coadministration of lacosamide with sodium channel-blocking antiseizure drugs may increase the risk for AV block, bradycardia, or ventricular tachyarrhythmias. Monitor ECG before beginning lacosamide and after lacosamide is titrated to steady-state. - fedratinib
fedratinib will increase the level or effect of lacosamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP3A4 substrates as necessary.
- fluconazole
fluconazole increases levels of lacosamide by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely. Consider decreasing lacosamide dose when coadministered with strong CYP2C9 inhibitors.
- fluorouracil
fluorouracil increases levels of lacosamide by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely. Consider decreasing lacosamide dose when coadministered with strong CYP2C9 inhibitors.
- flurbiprofen
flurbiprofen increases levels of lacosamide by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely. Consider decreasing lacosamide dose when coadministered with strong CYP2C9 inhibitors.
- fosamprenavir
fosamprenavir increases levels of lacosamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider decreasing lacosamide dose when coadministered with strong CYP3A4 inhibitors.
- fosphenytoin
fosphenytoin will decrease the level or effect of lacosamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
fosphenytoin increases toxicity of lacosamide by Other (see comment). Use Caution/Monitor. Comment: Coadministration of lacosamide with sodium channel-blocking antiseizure drugs may increase the risk for AV block, bradycardia, or ventricular tachyarrhythmias. Monitor ECG before beginning lacosamide and after lacosamide is titrated to steady-state. - gemfibrozil
gemfibrozil increases levels of lacosamide by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely. Consider decreasing lacosamide dose when coadministered with strong CYP2C9 inhibitors.
- ibuprofen
ibuprofen increases levels of lacosamide by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely. Consider decreasing lacosamide dose when coadministered with strong CYP2C9 inhibitors.
- ibuprofen IV
ibuprofen IV increases levels of lacosamide by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely. Consider decreasing lacosamide dose when coadministered with strong CYP2C9 inhibitors.
- imatinib
imatinib increases levels of lacosamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider decreasing lacosamide dose when coadministered with strong CYP3A4 inhibitors.
- indinavir
indinavir increases levels of lacosamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider decreasing lacosamide dose when coadministered with strong CYP3A4 inhibitors.
- indomethacin
indomethacin increases levels of lacosamide by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely. Consider decreasing lacosamide dose when coadministered with strong CYP2C9 inhibitors.
- isoniazid
isoniazid increases levels of lacosamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider decreasing lacosamide dose when coadministered with strong CYP3A4 inhibitors.
- istradefylline
istradefylline will increase the level or effect of lacosamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Istradefylline 40 mg/day increased peak levels and AUC of CYP3A4 substrates in clinical trials. This effect was not observed with istradefylline 20 mg/day. Consider dose reduction of sensitive CYP3A4 substrates.
- itraconazole
itraconazole increases levels of lacosamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider decreasing lacosamide dose when coadministered with strong CYP3A4 inhibitors.
- ketoconazole
ketoconazole increases levels of lacosamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Patients with renal or hepatic impairment who are taking strong CYP3A4 and CYP2C9 inhibitors may have a significant increase in exposure to lacosamide. Dose reduction may be necessary in these patients.
ketoconazole increases levels of lacosamide by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely. Patients with renal or hepatic impairment who are taking strong CYP3A4 and CYP2C9 inhibitors may have a significant increase in exposure to lacosamide. Dose reduction may be necessary in these patients. - lamotrigine
lamotrigine increases toxicity of lacosamide by Other (see comment). Use Caution/Monitor. Comment: Coadministration of lacosamide with sodium channel-blocking antiseizure drugs may increase the risk for AV block, bradycardia, or ventricular tachyarrhythmias. Monitor ECG before beginning lacosamide and after lacosamide is titrated to steady-state.
- lenacapavir
lenacapavir will increase the level or effect of lacosamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lencapavir may increase CYP3A4 substrates initiated within 9 months after last SC dose of lenacapavir, which may increase potential risk of adverse reactions of CYP3A4 substrates.
- levoketoconazole
levoketoconazole increases levels of lacosamide by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely. Patients with renal or hepatic impairment who are taking strong CYP3A4 and CYP2C9 inhibitors may have a significant increase in exposure to lacosamide. Dose reduction may be necessary in these patients.
levoketoconazole increases levels of lacosamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Patients with renal or hepatic impairment who are taking strong CYP3A4 and CYP2C9 inhibitors may have a significant increase in exposure to lacosamide. Dose reduction may be necessary in these patients. - lopinavir
lopinavir increases levels of lacosamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider decreasing lacosamide dose when coadministered with strong CYP3A4 inhibitors.
- lumacaftor/ivacaftor
lumacaftor/ivacaftor, lacosamide. affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. In vitro studies suggest that lumacaftor may induce and ivacaftor may inhibit CYP2C9 substrates. .
- mefenamic acid
mefenamic acid increases levels of lacosamide by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely. Consider decreasing lacosamide dose when coadministered with strong CYP2C9 inhibitors.
- methylphenidate transdermal
methylphenidate transdermal will increase the level or effect of lacosamide by decreasing metabolism. Modify Therapy/Monitor Closely. Consider decreasing the dose of these drugs when given coadministered with methylphenidate. Monitor for drug toxiticities when initiating or discontinuing methylphenidate.
- midazolam intranasal
midazolam intranasal, lacosamide. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase the risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect.
- mifepristone
mifepristone will increase the level or effect of lacosamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- mitotane
mitotane decreases levels of lacosamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments.
- nefazodone
nefazodone increases levels of lacosamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider decreasing lacosamide dose when coadministered with strong CYP3A4 inhibitors.
- nelfinavir
nelfinavir, lacosamide. Either increases levels of the other by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider decreasing lacosamide dose when coadministered with strong CYP3A4 inhibitors.
- nicardipine
nicardipine, lacosamide. Either increases levels of the other by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider decreasing lacosamide dose when coadministered with strong CYP3A4 inhibitors.
nicardipine increases levels of lacosamide by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely. Consider decreasing lacosamide dose when coadministered with strong CYP2C9 inhibitors. - nitisinone
nitisinone will increase the level or effect of lacosamide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Nitisinone inhibits CYP2C9. Caution if CYP2C9 substrate coadministered, particularly those with a narrow therapeutic index.
- orlistat
orlistat decreases levels of lacosamide by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Risk of convulsions.
- phenytoin
phenytoin increases toxicity of lacosamide by Other (see comment). Use Caution/Monitor. Comment: Coadministration of lacosamide with sodium channel-blocking antiseizure drugs may increase the risk for AV block, bradycardia, or ventricular tachyarrhythmias. Monitor ECG before beginning lacosamide and after lacosamide is titrated to steady-state.
- piroxicam
piroxicam increases levels of lacosamide by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely. Consider decreasing lacosamide dose when coadministered with strong CYP2C9 inhibitors.
- posaconazole
posaconazole, lacosamide. Either increases levels of the other by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider decreasing lacosamide dose when coadministered with strong CYP3A4 inhibitors.
- quinidine
quinidine, lacosamide. Either increases levels of the other by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider decreasing lacosamide dose when coadministered with strong CYP3A4 inhibitors.
- ritonavir
ritonavir increases levels of lacosamide by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Potential for increased toxicity. Use alternatives if available. Increased risk of PR prolongation and cardiac arrhythmias.
ritonavir, lacosamide. Either increases levels of the other by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider decreasing lacosamide dose when coadministered with strong CYP3A4 inhibitors. - rufinamide
rufinamide increases toxicity of lacosamide by Other (see comment). Use Caution/Monitor. Comment: Coadministration of lacosamide with sodium channel-blocking antiseizure drugs may increase the risk for AV block, bradycardia, or ventricular tachyarrhythmias. Monitor ECG before beginning lacosamide and after lacosamide is titrated to steady-state.
- saquinavir
saquinavir increases levels of lacosamide by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Potential for increased toxicity. Use alternatives if available. Increased risk of PR prolongation and cardiac arrhythmias.
saquinavir increases levels of lacosamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider decreasing lacosamide dose when coadministered with strong CYP3A4 inhibitors. - sevelamer
sevelamer decreases levels of lacosamide by increasing elimination. Use Caution/Monitor.
- sparsentan
sparsentan will decrease the level or effect of lacosamide by affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor. Sparsentan (a CYP2C9 inducer) decreases exposure of CYP2C9 substrates and reduces efficacy related to these substrates.
- stiripentol
stiripentol, lacosamide. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Stiripentol is a CYP3A4 inhibitor and inducer. Monitor CYP3A4 substrates coadministered with stiripentol for increased or decreased effects. CYP3A4 substrates may require dosage adjustment.
- sulfadiazine
sulfadiazine increases levels of lacosamide by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely. Consider decreasing lacosamide dose when coadministered with strong CYP2C9 inhibitors.
- sulfamethoxazole
sulfamethoxazole increases levels of lacosamide by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely. Consider decreasing lacosamide dose when coadministered with strong CYP2C9 inhibitors.
- tazemetostat
tazemetostat will decrease the level or effect of lacosamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
- tecovirimat
tecovirimat will decrease the level or effect of lacosamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tecovirimat is a weak CYP3A4 inducer. Monitor sensitive CYP3A4 substrates for effectiveness if coadministered.
- tipranavir
tipranavir increases levels of lacosamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider decreasing lacosamide dose when coadministered with strong CYP3A4 inhibitors.
- tolbutamide
tolbutamide increases levels of lacosamide by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely. Consider decreasing lacosamide dose when coadministered with strong CYP2C9 inhibitors.
- topiramate
topiramate increases toxicity of lacosamide by Other (see comment). Use Caution/Monitor. Comment: Coadministration of lacosamide with sodium channel-blocking antiseizure drugs may increase the risk for AV block, bradycardia, or ventricular tachyarrhythmias. Monitor ECG before beginning lacosamide and after lacosamide is titrated to steady-state.
- voriconazole
voriconazole increases levels of lacosamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider decreasing lacosamide dose when coadministered with strong CYP3A4 inhibitors.
voriconazole increases levels of lacosamide by affecting hepatic enzyme CYP2C9/10 metabolism. Modify Therapy/Monitor Closely. Consider decreasing lacosamide dose when coadministered with strong CYP2C9 inhibitors. - zonisamide
zonisamide increases toxicity of lacosamide by Other (see comment). Use Caution/Monitor. Comment: Coadministration of lacosamide with sodium channel-blocking antiseizure drugs may increase the risk for AV block, bradycardia, or ventricular tachyarrhythmias. Monitor ECG before beginning lacosamide and after lacosamide is titrated to steady-state.
Minor (22)
- acetaminophen
lacosamide decreases levels of acetaminophen by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites.
- acetaminophen IV
lacosamide decreases levels of acetaminophen IV by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites.
- acetaminophen rectal
lacosamide decreases levels of acetaminophen rectal by increasing metabolism. Minor/Significance Unknown. Enhanced metabolism incr levels of hepatotoxic metabolites.
- acetazolamide
acetazolamide will increase the level or effect of lacosamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- anastrozole
anastrozole will increase the level or effect of lacosamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- atracurium
lacosamide decreases effects of atracurium by pharmacodynamic antagonism. Minor/Significance Unknown.
- biotin
lacosamide decreases levels of biotin by unspecified interaction mechanism. Minor/Significance Unknown. Biotin supplementation may be necessary.
- cisatracurium
lacosamide decreases effects of cisatracurium by pharmacodynamic antagonism. Minor/Significance Unknown.
- cyanocobalamin
lacosamide decreases levels of cyanocobalamin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- cyclophosphamide
cyclophosphamide will increase the level or effect of lacosamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- dexmethylphenidate
dexmethylphenidate increases effects of lacosamide by decreasing metabolism. Minor/Significance Unknown.
- larotrectinib
larotrectinib will increase the level or effect of lacosamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- levocarnitine
lacosamide decreases levels of levocarnitine by unspecified interaction mechanism. Minor/Significance Unknown.
- onabotulinumtoxinA
lacosamide decreases effects of onabotulinumtoxinA by pharmacodynamic antagonism. Minor/Significance Unknown.
- pancuronium
lacosamide decreases effects of pancuronium by pharmacodynamic antagonism. Minor/Significance Unknown.
- rapacuronium
lacosamide decreases effects of rapacuronium by pharmacodynamic antagonism. Minor/Significance Unknown.
- ribociclib
ribociclib will increase the level or effect of lacosamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.
- rocuronium
lacosamide decreases effects of rocuronium by pharmacodynamic antagonism. Minor/Significance Unknown.
- sage
sage decreases effects of lacosamide by pharmacodynamic antagonism. Minor/Significance Unknown. Theoretical interaction; some species of sage may cause convulsions.
- serdexmethylphenidate/dexmethylphenidate
serdexmethylphenidate/dexmethylphenidate increases effects of lacosamide by decreasing metabolism. Minor/Significance Unknown.
- succinylcholine
lacosamide decreases effects of succinylcholine by pharmacodynamic antagonism. Minor/Significance Unknown.
- vecuronium
lacosamide decreases effects of vecuronium by pharmacodynamic antagonism. Minor/Significance Unknown.
Adverse Effects
>10%
Tablets and oral solution
- Dizziness (16-53%)
- Diplopia (6-16%)
- Blurred vision (2-16%)
- Nausea (7-17%)
- Vomiting (6-16%)
- Fatigue (7-15%)
- Ataxia (11-14%)
- Nystagmus (2-10%)
IV
- Fatigue (20-63%)
- Somnolence (26-34%)
- Headache (4-16%)
- Diplopia (4-20%)
- Nausea (14-24%)
- Dry mouth (6-12%)
- Vomiting (4-12%)
- Fatigue (12-18%)
- Chest pain (3-12%)
1-10%
Tablets and oral solution
- Nystagmus (2-10%)
- Memory impairment (1-6%)
- Balance disorder (1-6%)
- Diarrhea (3-5%)
- Gait disturbance (<1-4%)
- Asthenia (1-3%)
- Vertigo (1-4%)
- Pruritus (2-3%)
- Depression (2%)
IV
- Oral paresthesia (4-8%)
- Oral hypoesthesia (5-8%)
- Diarrhea (4-8%)
- Paresthesia (4-8%)
- Gait disturbance (2-8%)
- Hyperhidrosis (2-8%)
- Tremor (4-6%)
- Abnormal coordination (3-6%)
- Pruritus (4-6%)
Frequency Not Reported
Blood and lymphatic system disorders: Neutropenia, anemia
Cardiac disorders: Palpitations Ear and labyrinth disorders: Tinnitus
Gastrointestinal disorders: Constipation, dyspepsia, dry mouth, oral hypoaesthesia
General disorders and administration site conditions: Irritability, pyrexia, feeling drunk
Injury, poisoning, and procedural complications: Fall
Musculoskeletal and connective tissue disorders: Muscle spasms
Nervous system disorders: Paresthesia, cognitive disorder, hypesthesia, dysarthria, disturbance in attention, cerebellar syndrome
Psychiatric disorders: Confusional state, mood altered, depressed mood
Postmarketing Reports
Blood and lymphatic system disorders: Agranulocytosis
Psychiatric disorders: Aggression, agitation, hallucination, insomnia, psychotic disorder
Neurologic disorders: New or worsening seizures, dyskinesia
Skin and subcutaneous tissue disorders: Angioedema, rash, urticaria, Stevens-Johnson syndrome, toxic epidermal necrolysis
Warnings
Contraindications
None
Cautions
Increase the risk of suicidal thoughts or behavior; monitor for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior
Dizziness and ataxia reported; may impair ability to perform hazardous tasks; if loading dose is clinically indicated, administer with medical supervision; may increase incidence of adverse reactions, including CNS adverse reactions such as dizziness and ataxia
Blurred vision and diplopia may occur during therapy; consider increased monitoring in patients with preexisting ocular conditions or vision-related issues
Oral solution contains aspartame, a source of phenylalanine; 200 mg dose (20 mL) contains 0.32 mg of phenylalanine
Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), also known as multi-organ hypersensitivity, reported with antiepileptic drugs; some of these events have been fatal or life- threatening; monitor for signs and symptoms of possible disparate manifestations associated with lymphatic hepatic, renal, and/or hematologic organ systems; may require gradual discontinuation and conversion to alternate therapy
Use caution in renal and hepatic impairment; dosage adjustments may be required
Withdraw gradually over 1 week; do not discontinue abruptly because of risk for increased frequency of seizures
Cardiac rhythm and conduction
- All patients for whom loading dose clinically indicated, administer loading dose with medical supervision; may increase incidence of adverse reactions, including cardiovascular adverse reactions
- Both atrial fibrillation and atrial flutter reported in open label partial-onset seizure trials and in postmarketing experience; therapy may predispose to atrial arrhythmias (atrial fibrillation or flutter), especially in patients with diabetic neuropathy and/or cardiovascular diseaseCardiac arrhythmias reported, including bradycardia, AV block, and ventricular tachyarrhythmia, which have rarely resulted in asystole, cardiac arrest, and death
- Most, although not all, cases occurred in patients with underlying proarrhythmic conditions, or in those taking concomitant medications that affect cardiac conduction or prolong the PR interval
- Events occurred with both PO or IV administration and at prescribed doses, as well as in the setting of overdose
- Caution with underlying proarrhythmic conditions (eg, marked first-degree AV block, second-degree or higher AV block and sick sinus syndrome without pacemaker), severe cardiac disease, including myocardial ischemia or heart failure, or structural heart disease, and cardiac sodium disorders (eg, Brugada Syndrome)
Drug interactions overview
- Patients with renal or hepatic impairment who are taking strong CYP3A4 and CYP2C9 inhibitors may have a significant increase in exposure to lacosamide; dose reduction may be necessary
-
Concomitant medications that prolong PR interval
- Use with caution when administered concomitantly with medications that affect cardiac conduction, including sodium channel blockers, beta-blockers, calcium channel blockers, potassium channel blockers, and medications that prolong the PR interval; obtain an ECG before beginning therapy, and after titrating to steady-state maintenance dose, in such patients; closely monitor if intravenous route used to administer medication
- Obtain an ECG before initiating and after titrated to steady-state; additionally, monitor closely if administered IV
Pregnancy & Lactation
Pregnancy
There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (AEDs); to enroll in the North American Antiepileptic Drug (NAAED) pregnancy registry by calling 1-888-233-2334 or visiting http://www.aedpregnancyregistry.org/
Available data from NAAED pregnancy registry, a prospective cohort study, case reports, and a case series in pregnant women are insufficient to identify a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes
Lacosamide produced developmental toxicity (increased embryofetal and perinatal mortality, growth deficit) in rats following administration during pregnancy
Developmental neurotoxicity was observed in rats following administration during a period of postnatal development corresponding to the third trimester of human pregnancy
Lactation
Data from published literature indicate that lacosamide is present in human milk; there are reports of increased sleepiness in breastfed infants exposed to lacosamide; there is no information on effects of lacosamide on milk production
Studies in lactating rats have shown excretion of lacosamide and/or its metabolites in milk
Developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for lacosamide and any potential adverse effects on the breastfed infant from lacosamide or from the underlying maternal condition
Monitor infants exposed to drugs through breastmilk for excess sedation
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Antiepileptic effects unknown; may slowly inactivate voltage-gated Na channels
Binds to collapsin response mediator protein-2 (CRMP-2), a phosphoprotein that is expressed mainly in the nervous system and is involved in neuronal differentiation and control of axonal outgrowth
Absorption
Bioavailability: ~100%
Peak plasma time: 1-4 hr
Distribution
Protein bound: <15%
Vd: 0.6 L/kg
Metabolism
Predominantly by CYP isoenzymes 3A4 and 2C9; also 2C19
Major metabolite: O-desmethyl-lacosamide (inactive)
Elimination
Half-life: 13 hr
Primarily eliminated by renal excretion and biotransformation
Dialyzable: Yes (hemodialysis)
-
Excretion
- Vimpat: 95% urine; <5% feces
- Motpoly XR: 95% urine; <0.5% feces; major compounds excreted were unchanged lacosamide (~40% of the dose), O-desmethyl metabolite (~ 30%), and a structurally unknown polar fraction (~20%)
Administration
IV Compatibility
0.9% NaCl, D5W, LR
IV Preparation
May be administered without dilution or diluted in compatible solutions; (see IV Compatibility)
Visually inspect for particulate matter and discoloration prior to administration, whenever solution and container permit
Product with particulate matter or discoloration should not be used
Vials is for single-dose only; discard any unused portion of lacosamide injection
IV Administration
IV lacosamide may cause bradycardia or AV bock in patients with underlying cardiac disease
Monitor infusion closely patients with known cardiac conduction problems, on concomitant medications that prolong PR interval, or with severe cardiac disease (eg, myocardial ischemia, heart failure)
Adults
- Administer by IV infusion over 30-60 minutes
- May administer as rapidly as 15 minutes if needed
Children
- Administer by IV infusion over 30-60 minutes
- Infusion duration <30 minutes not recommended
Oral Administration
Tablets or oral solution: Take with or without food
Swallow tablets whole with liquid; do not divide tablets
Swallow capsules whole with liquid; do not open, chew, or crush
Oral solution
- Use calibrated measuring device to measure and deliver the prescribed dose accurately
- May be administered using a nasogastric tube or gastrostomy tube; discard any unused lacosamide oral solution remaining after 6 months of first opening the bottle
Storage
Tablet: Store at room temperature, 20-25°C (68-77°F); excursions permitted between 15-30°C (59-86°F); do not freeze lacosamide oral solution
Capsules: Store at room temperature, 20-25°C (68-77°F); excursions permitted between 15-30°C (59-86°F); do not freeze lacosamide oral solution
Oral solution: Store at room temperature, 20-25°C (68-77°F); excursions permitted between 15-30°C (59-86°F); do not freeze lacosamide oral solution; discard any unused oral solution remaining after 6 months of first opening the bottle
Injection: Store at room temperature, 20-25°C (68-77°F); excursions are permitted between 15-30°C (59-86°F); do not freeze
Diluted IV solution: Store at room temperature, 20-25°C (68-77°F); for up to 4 hr
Images
| BRAND | FORM. | UNIT PRICE | PILL IMAGE |
|---|---|---|---|
| Motpoly XR oral - | 200 mg capsule |  | |
| Motpoly XR oral - | 150 mg capsule |  | |
| Motpoly XR oral - | 100 mg capsule |  | |
| lacosamide oral - | 10 mg/mL solution |  | |
| lacosamide oral - | 150 mg tablet |  | |
| lacosamide oral - | 200 mg tablet |  | |
| lacosamide oral - | 100 mg tablet |  | |
| lacosamide oral - | 200 mg tablet |  | |
| lacosamide oral - | 150 mg tablet |  | |
| lacosamide oral - | 100 mg tablet |  | |
| lacosamide oral - | 200 mg tablet |  | |
| lacosamide oral - | 200 mg tablet |  | |
| lacosamide oral - | 100 mg tablet |  | |
| lacosamide oral - | 10 mg/mL solution |  | |
| lacosamide oral - | 150 mg tablet |  | |
| lacosamide oral - | 50 mg tablet |  | |
| lacosamide oral - | 200 mg tablet |  | |
| lacosamide oral - | 150 mg tablet |  | |
| lacosamide oral - | 100 mg tablet |  | |
| lacosamide oral - | 50 mg tablet |  | |
| lacosamide oral - | 200 mg tablet |  | |
| lacosamide oral - | 150 mg tablet |  | |
| lacosamide oral - | 100 mg tablet |  | |
| lacosamide oral - | 50 mg tablet |  | |
| Vimpat oral - | 100 mg tablet |  | |
| Vimpat oral - | 50 mg tablet |  | |
| Vimpat oral - | 150 mg tablet |  | |
| Vimpat oral - | 200 mg tablet |  | |
| lacosamide intravenous - | 200 mg/20 mL vial |  | |
| lacosamide intravenous - | 200 mg/20 mL vial |  | |
| lacosamide intravenous - | 200 mg/20 mL vial |  | |
| Vimpat intravenous - | 200 mg/20 mL vial |  |
Copyright © 2010 First DataBank, Inc.
Patient Handout
lacosamide oral
LACOSAMIDE - ORAL
(la-KOE-sa-mide)
COMMON BRAND NAME(S): Vimpat, Motpoly XR
USES: Lacosamide is used to prevent and control seizures. It is an anticonvulsant or antiepileptic drug. It works by reducing the spread of seizure activity in the brain.
HOW TO USE: Read the Medication Guide provided by your pharmacist before you start taking lacosamide and each time you get a refill. If you have any questions, consult your doctor or pharmacist.Take the liquid and immediate-release tablets by mouth with or without food as directed by your doctor, usually twice daily.The manufacturer directs to swallow the tablet form of this medication whole. However, many similar drugs (immediate-release tablets) can be split/crushed. Follow your doctor's directions on how to take this medication.If you are using the liquid form of this medication, carefully measure the dose using a special measuring device/spoon. Do not use a household spoon because you may not get the correct dose.If you are using the extended-release capsules, take the medication by mouth with or without food as directed by your doctor, usually once daily. Swallow the capsules whole. Do not open, crush, or chew the capsules. Doing so can release all of the drug at once, increasing the risk of side effects.The dosage is based on your medical condition and response to treatment. Children's dosage is also based on weight. To reduce your risk of side effects, your doctor may direct you to start this medication at a low dose and gradually increase your dose. Follow your doctor's instructions carefully.This medication works best when the amount of drug in your body is kept at a constant level. Take this drug at evenly spaced intervals. To help you remember, take it at the same time(s) each day.Do not stop taking this medication without consulting your doctor. Seizures may become worse when the drug is suddenly stopped. Your dose may need to be gradually decreased. Consult your doctor or pharmacist for more details.Though it helps many people, this medication may sometimes cause addiction. This risk may be higher if you have a substance use disorder (such as overuse of or addiction to drugs/alcohol). Do not increase your dose, take it more often, or use it for a longer time than prescribed. Properly stop the medication when so directed.Tell your doctor right away if your seizure control worsens (such as the number of seizures increases).
SIDE EFFECTS: Dizziness, drowsiness, blurred/double vision, nausea, vomiting, tiredness, loss of balance, difficulty walking, shakiness (tremor), or memory problems may occur. These side effects are more common when you first start taking the drug and usually lessen as your body adjusts to the medication. If any of these effects last or get worse, notify your doctor or pharmacist promptly.Remember that this medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.Get medical help right away if you have any very serious side effects, including: fast/slow/irregular/pounding heartbeat, chest pain, shortness of breath, severe dizziness, fainting.A small number of people who take anticonvulsants for any condition (such as seizure, bipolar disorder, pain) may experience depression, suicidal thoughts/attempts, or other mental/mood problems. Tell your doctor right away if you or your family/caregiver notice any unusual/sudden changes in your mood, thoughts, or behavior including signs of depression, suicidal thoughts/attempts, thoughts about harming yourself.A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: fever, swollen lymph nodes, rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
PRECAUTIONS: Before taking lacosamide, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients (such as propylene glycol), which can cause allergic reactions or other problems. Talk to your pharmacist for more details.Before using this medication, tell your doctor or pharmacist your medical history, especially of: heart problems (such as chest pain, sick sinus syndrome, heart failure, AV block, irregular heartbeat), liver problems, kidney problems (including dialysis treatment), mental/mood problems (such as depression, psychosis), personal or family history of a substance use disorder (such as overuse of or addiction to drugs/alcohol).This drug may make you dizzy or drowsy or blur your vision. Alcohol or marijuana (cannabis) can make you more dizzy or drowsy. Do not drive, use machinery, or do anything that needs alertness or clear vision until you can do it safely. Avoid alcoholic beverages. Talk to your doctor if you are using marijuana (cannabis).The liquid form of this medication may contain aspartame. If you have phenylketonuria (PKU) or any other condition that requires you to limit/avoid aspartame (or phenylalanine) in your diet, ask your doctor or pharmacist about using this medication safely.Before having surgery, tell your doctors or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).During pregnancy, this medication should be used only when clearly needed. Discuss the risks and benefits with your doctor.This drug passes into breast milk and may have undesirable effects on a nursing infant. Consult your doctor before breast-feeding.
DRUG INTERACTIONS: Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.A product that may interact with this drug is: orlistat.Tell your doctor or pharmacist if you are taking other products that cause drowsiness including alcohol, marijuana (cannabis), antihistamines (such as cetirizine, diphenhydramine), drugs for sleep or anxiety (such as alprazolam, diazepam, zolpidem), muscle relaxants, and opioid pain relievers (such as codeine).Check the labels on all your medicines (such as cough-and-cold products) because they may contain drowsiness-causing ingredients. Ask your pharmacist about using those products safely.
OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center. Symptoms of overdose may include: severe nausea/vomiting, difficulty waking up, confusion, irregular heartbeat, very slow breathing.
NOTES: Do not share this medication with others. Sharing it is against the law.Lab and/or medical tests (such as liver/kidney function, EKG) may be done while you are taking this medication. Keep all medical and lab appointments. Consult your doctor for more details.
MISSED DOSE: If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Take your next dose at the regular time. Do not double the dose to catch up.
STORAGE: Store at room temperature away from light and moisture. Do not store in the bathroom. Do not freeze the liquid form of this medication. The liquid form should be used/discarded within 6 months after opening. Keep all medications away from children and pets.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.
MEDICAL ALERT: Your condition can cause complications in a medical emergency. For information about enrolling in MedicAlert, call 1-888-633-4298 (US) or 1-800-668-1507 (Canada).
Information last revised October 2023. Copyright(c) 2023 First Databank, Inc.
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
